Pharmacopeia, Inc.

As of December 23, 2008, Pharmacopeia, Inc. was acquired by Ligand Pharmaceuticals Incorporated. Pharmacopeia, Inc. is a biopharmaceutical company that engages in the discovery and development of therapeutics to address significant medical needs. Its internal program portfolio comprises PS433540, a dual-acting angiotensin and endothelin receptor antagonist, which is in phase II clinical development for the treatment of cardiovascular and renal diseases, including hypertension and diabetic nephropathy; and PS178990, a muscle selective SARM agonists that is in phase I clinical development. The company’s products also include PS031291, a preclinical development product for the treatment of multiple myeloma and various inflammatory diseases, including rheumatoid arthritis; and JAK3 inhibitors for T-cell and cytokine mediated dermatologic and ocular diseases, such as psoriasis and dry eye. The company has strategic alliances with Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. Pharmacopeia, Inc. was formerly known as Pharmacopeia Drug Discovery, Inc. and changed its name to Pharmacopeia, Inc. in May, 2007. Pharmacopeia, Inc. was founded in 1993 and is based in Cranbury, New Jersey.